As has been the case for the past several years, industry experts will be focused on Merck at the 44 th Annual JP Morgan ...

Merck (MRK) looks undervalued amid 2028 Keytruda patent fears—strong Q3 results, pipeline wins, and 12x P/E suggest upside.

An Auckland woman who is self-funding treatment for her rare, aggressive breast cancer is fed up after years of asking the ...

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is trading at three year highs despite market volatility, responding to breakthrough innovations and increased deals involving NASDAQ biotech stocks.

Consuming more sugar does not feed cancer cells, but the concern is that it does cause inflammation in the body if you're eating excess sugar in your diet. It is those inflammatory changes that are ...

High levels of IB6 are often found in NSCLC, making it a good target for treatment. A preclinical study found that in lung cancer, IB6 was correlated with interleukin-8 levels and promoted cancer cell ...

The RELATIVITY-098 trial showed no RFS improvement with nivolumab plus relatlimab versus nivolumab alone in resected stage ...

NASA opens the International Space Station for scientists and researchers, inviting them to use the benefits of microgravity ...

This year, there was a surge of new lung cancer treatments, more options for patients with earlier-stage disease, and growing ...

Following the positive outcome, Pfizer and Astellas will seek approval of Padcev-Keytruda in MIBC regardless of a patient’s cisplatin eligibility.

“PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility,” by Astellas Pharma Inc. News release; Dec. 17, 2025.

Merck says Keytruda plus Padcev improved survival and response rates versus chemotherapy in a Phase 3 muscle-invasive bladder ...